

IMPACT FACTOR 3.4

Indexed in: PubMed



an Open Access Journal by MDPI

Recent Advances in Diagnosis, Treatment and Observation in Otorhinolaryngology

Guest Editor:

Prof. Dr. Luca Malvezzi

1. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy 2. Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy 3. Otorhinolaryngology Head and Neck Surgery Unit, Casa di Cura Humanitas San Pio X, Via Francesco Nava 31, 20159 Milan, Italy

Deadline for manuscript submissions:

closed (1 October 2023)

Message from the Guest Editor

Throughout the last decade, chronic rhinosinusitis has been recognized as a complex model of inflammation, and the clinical interest in this pathology has increased, as has the attention of the scientific community. With the awareness of the concept of united airways disease and the recent advent of biological therapies, namely target therapies, we have definitively understood the importance of multidisciplinary and personalized diagnostic—therapeutic management. This is mandatory to identify the patient's immunological profile by assisting in the clinical experience of several specialist figures, and, at the same time, to avoid excesses in the administration of systemic steroids or improperly planned and recurrent surgical interventions.

The purposes of this Special Issue of the *Journal of Personalized Medicine* will be to emphasize the role of the diagnostic process and related clinical research aspects regarding the unmet needs of the patients and the pathology, to understand the current aspects of therapeutic management, and to look at future therapeutic perspectives, including the role of surgery.







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

Contact Us